Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Xeris Biopharma Holdings (XERS) Cost of Revenue (2020 - 2025)

Xeris Biopharma Holdings' Cost of Revenue history spans 6 years, with the latest figure at $10.9 million for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue rose 15.5% year-over-year to $10.9 million, compared with a TTM value of $42.6 million through Dec 2025, up 15.58%, and an annual FY2025 reading of $42.6 million, up 15.58% over the prior year.
  • Cost of Revenue for Q4 2025 was $10.9 million at Xeris Biopharma Holdings, roughly flat from $11.0 million in the prior quarter.
  • The five-year high for Cost of Revenue was $13.6 million in Q3 2024, with the low at $1.8 million in Q1 2021.
  • Average Cost of Revenue over 5 years is $7.2 million, with a median of $6.9 million recorded in 2022.
  • Year-over-year, Cost of Revenue surged 243.54% in 2022 and then fell 19.11% in 2025.
  • Tracing XERS's Cost of Revenue over 5 years: stood at $4.9 million in 2021, then grew by 28.68% to $6.3 million in 2022, then grew by 20.33% to $7.6 million in 2023, then rose by 25.2% to $9.5 million in 2024, then increased by 15.5% to $10.9 million in 2025.
  • Per Business Quant, the three most recent readings for XERS's Cost of Revenue are $10.9 million (Q4 2025), $11.0 million (Q3 2025), and $11.9 million (Q2 2025).